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lioblastoma (GBM) is among the most lethal
of cancers, and the most common primary
malignancy of the central nervous system
(CNS) in adults.1 An estimated 22,810 new cases of
malignant primary CNS tumor will be diagnosed in
the United States in 2014, with an estimated 9,600 to
11,200 new cases of GBM.1,2
Prognosis for patients with GBM continues to be
very poor, despite modest therapeutic improve-
ments over the last 3 decades. Currently, there is
no cure for GBM, and no recognized standard of care
for recurrent disease, in spite of the fact that a
number of therapies such as carmustine wafers,
intracavitary balloon brachytherapy, and bevacizu-
mab have been approved by the US Food and Drug
Administration (FDA) for this indication. The current
standard treatment for newly diagnosed GBM is
maximal surgical resection followed by concomitant
radiotherapy and chemotherapy (temozolomide),
then adjuvant temozolomide.3,4 The median overall
survival (OS) with this treatment regimen is 14.2 to
14.6 months, with a 2-year OS rate of 26% to 27%.5,6
Historically, 5-year relative OS rates for GBM have
been very low, generally less than 5% in population-
based studies.7 Somewhat higher (albeit still low) 5-
year OS rates have been reported in recent clinical
trials, in the range of 4.6% to 11.1%.1,5,8,9 Higher 5-
year OS rates are observed in individuals diagnosed
with GBM at a younger age (o45-50 years), those
who are more functional, and those with methyla-
tion of the promoter region of the MGMT gene.1,9
Virtually all cases of GBM eventually recur despite
optimal treatment.10 Median progression-free survi-
val (PFS) is 9 to 11 weeks for patients with recurrent
GBM, with475% of patients suffering a treatment
failure 26 weeks after beginning recurrent GBM0093-7754/ - see front matter
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Open access under CC BY-NC-ND license.therapy.11 When feasible, re-resection or re-
irradiation may be attempted.12 However, radiother-
apy is often unable to effectively control the disease
long-term, probably due to an inability to detect the
pattern of GBM spread.10 A number of cytotoxic
agents have been tried, none with significant activ-
ity, including temozolomide rechallenge, procarba-
zine, lomustine, and vincristine.10,12 Recently,
bevacizumab received accelerated approval from
the FDA as a therapy for recurrent GBM, based on
tumor response and PFS data from two phase II
trials.2,10 However, it now appears that improved
PFS with bevacizumab may not translate into
improved OS for patients with newly diagnosed
GBM, and the survival prolongation in the recurrent
setting is modest at best.2,13–15 Even recurrent GBM
tumors initially responsive to bevacizumab inevitably
progress within a few weeks to months,10 leaving
the patient with few salvage therapy options. Sub-
sequent chemotherapy is uniformly ineffective,2,16,17
with a median OS after bevacizumab failure of only
10 weeks for recurrent GBM patients.18
The BELOB trial was the first to report ran-
domized data regarding the role of bevacizumab on
overall survival in 153 recurrent GBM patients who
were randomized to lomustine, bevacizumab, or
combination treatment. Nine-month overall survival
was 43% in the lomustine group, 38% in the bev-
acizumab group, and 59% in the bevacizumab and
lomustine group. The authors concluded that
whereas bevacizumab alone did not warrant further
phase III evaluation in this context, the combination
of lomustine and bevacizumab probably does.19
Salvage with re-irradiation also has been attempted
for recurrent GBM, with mixed results, and combi-
nation salvage approaches with reirradiation and
bevacizumab are underway.
Clearly there is a need for new treatment options
for patients with recurrent GBM, and especially so
for those failing bevacizumab therapy. NovoTTF
Therapy is a novel antimitotic therapy that utilizes
low-intensity, intermediate-frequency, alternating
electric fields (tumor-treating fields [TTFields]) to
selectively kill or arrest the growth of rapidly divid-
ing cells.20,21 In 2011, the NovoTTF-100A System™
(Novocure Ltd., Haifa, Israel) was approved by the
FDA for the treatment of recurrent GBM based onS1-S3 S1
M. Mehta and S. BremS2the findings from a phase III trial; the trial was
originally designed to demonstrate an improvement
in survival. The study showed that the NovoTTF-
100A System was as effective as chemotherapy in
extending overall survival and PFS, but without the
systemic side effects of chemotherapy and with a
better quality of life.22
The current supplement is intended to provide an
overview of available knowledge concerning the use
of NovoTTF Therapy for the treatment of recurrent
GBM, as well as providing insights into its develop-
ment for the treatment of lung cancer. More specif-
ically, the first article in the supplement by Mrugala
and coauthors discusses findings from the postmar-
keting Patient Registry Dataset (PRiDe), looking at
NovoTTF Therapy use in the United States after
product approval (October 2011–November 2013).
This paper provides information about NovoTTF
Therapy when used in clinical practice to treat
recurrent GBM, comparing efficacy and tolerability
outcomes with those reported in the pivotal phase
III clinical trial, as well as looking at patient com-
pliance and the impact of compliance on survival
outcomes. The next article in the supplement, by
Vymazal and coauthors, takes a closer look at the
response patterns observed with NovoTTF Therapy
in recurrent GBM patients from the phase III and
earlier pilot study, as well as examining the relation-
ships between compliance, response, and OS. The
third article by Kanner and coauthors further ana-
lyzes data from the pivotal phase III trial, including
an analysis of median OS in the modified intention-
to-treat population and post-hoc compliance ana-
lyses for the intention-to-treat population. In each
of these articles, special emphasis is placed on the
identification of patient, tumor, and treatment char-
acteristics that result in a high response to NovoTTF
Therapy and improved long-term survival. The final
article in the supplement, by Giladi and coauthors,
explores preclinical insights into NovoTTF Therapy
for the treatment of lung cancer.
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